Financial Analysis: Gilead Sciences (GILD) and The Competition
Gilead Sciences (NASDAQ: GILD) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Gilead Sciences to similar companies based on the strength of its analyst recommendations, earnings, profitability, dividends, institutional ownership, valuation and risk.
This table compares Gilead Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gilead Sciences Competitors||-5,397.16%||-436.02%||-41.59%|
Volatility and Risk
Gilead Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Gilead Sciences’ competitors have a beta of 6.56, indicating that their average share price is 556% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Gilead Sciences and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gilead Sciences Competitors||768||3070||11275||227||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 24.40%. Given Gilead Sciences’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Gilead Sciences and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Gilead Sciences Competitors||$290.00||$35.57||-5.70|
Gilead Sciences has higher revenue and earnings than its competitors. Gilead Sciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
74.3% of Gilead Sciences shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 1.3% of Gilead Sciences shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Gilead Sciences pays an annual dividend of $2.08 per share and has a dividend yield of 2.8%. Gilead Sciences pays out 23.7% of its earnings in the form of a dividend. As a group, “Bio Therapeutic Drugs” companies pay a dividend yield of 2.8% and pay out 23.7% of their earnings in the form of a dividend.
Gilead Sciences beats its competitors on 7 of the 13 factors compared.
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.